{"id":21319,"date":"2026-01-02T23:06:51","date_gmt":"2026-01-02T21:06:51","guid":{"rendered":"https:\/\/www.maatpharma.com\/professionnels-de-la-sante\/"},"modified":"2026-04-07T17:23:52","modified_gmt":"2026-04-07T15:23:52","slug":"professionnels-de-la-sante","status":"publish","type":"page","link":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/","title":{"rendered":"Professionnels de la sant\u00e9"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"21319\" class=\"elementor elementor-21319 elementor-17981\" data-elementor-settings=\"{&quot;element_pack_global_tooltip_width&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_tablet_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_mobile_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_padding&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_tablet_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_mobile_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_tablet_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_mobile_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true}}\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3991354 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default elementor-section-items-middle wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"3991354\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;shape_divider_bottom&quot;:&quot;curve&quot;,&quot;shape_divider_bottom_negative&quot;:&quot;yes&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t<div class=\"elementor-shape elementor-shape-bottom\" aria-hidden=\"true\" data-negative=\"true\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1000 100\" preserveAspectRatio=\"none\">\n\t<path class=\"elementor-shape-fill\" d=\"M500,97C126.7,96.3,0.8,19.8,0,0v100l1000,0V1C1000,19.4,873.3,97.8,500,97z\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5fa12a4\" data-id=\"5fa12a4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9498dbe elementor-invisible elementor-widget elementor-widget-heading\" data-id=\"9498dbe\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;,&quot;_animation_delay&quot;:500}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Professionnels de la sant\u00e9\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0fcd1b8 elementor-widget elementor-widget-heading\" data-id=\"0fcd1b8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Cette page est destin\u00e9e aux professionnels de la sant\u00e9.<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-fbc882a e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-parent\" data-id=\"fbc882a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-32bcae9 elementor-widget elementor-widget-text-editor\" data-id=\"32bcae9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\"><a href=\"https:\/\/www.maatpharma.com\/fr\/patients-et-professionnels-de-sante\/\"><span style=\"text-decoration: underline;\"><strong>\u27a1 Revenir \u00e0 Patients et Professionnels de sant\u00e9<\/strong><\/span><\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2a297a5 elementor-section-height-min-height elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-items-middle wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"2a297a5\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-5e036a1\" data-id=\"5e036a1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#pathologie&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-section elementor-inner-section elementor-element elementor-element-e8c5453 elementor-section-full_width elementor-section-height-min-height elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"e8c5453\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#pathologie&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-b45e340\" data-id=\"b45e340\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-bf0ca1c elementor-widget elementor-widget-heading\" data-id=\"bf0ca1c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\"><a href=\"#pathologie\">GvHD : Pathologie et \u00e9pid\u00e9miologie<\/a><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-d1d76bb\" data-id=\"d1d76bb\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#microbiote&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-section elementor-inner-section elementor-element elementor-element-80c75fd elementor-section-height-min-height elementor-section-boxed elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"80c75fd\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#microbiote&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-6ef15e7\" data-id=\"6ef15e7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-134015f elementor-widget elementor-widget-heading\" data-id=\"134015f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\"><a href=\"#microbiote\">Microbiome intestinal et cancers du sang<\/a><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-558f405\" data-id=\"558f405\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#EAP&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-section elementor-inner-section elementor-element elementor-element-0ebafe9 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"0ebafe9\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#EAP&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-8003e7b\" data-id=\"8003e7b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ce51c88 elementor-widget elementor-widget-heading\" data-id=\"ce51c88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\"><a href=\"#EAP\">Programme d'acc\u00e8s anticip\u00e9<\/a><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-6f5f184\" data-id=\"6f5f184\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#essais&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-section elementor-inner-section elementor-element elementor-element-bb7ab23 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"bb7ab23\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div data-ep-wrapper-link=\"{&quot;url&quot;:&quot;#essais&quot;,&quot;is_external&quot;:&quot;&quot;,&quot;nofollow&quot;:&quot;&quot;,&quot;custom_attributes&quot;:&quot;&quot;}\" style=\"cursor: pointer\" class=\"bdt-element-link elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-89d526b\" data-id=\"89d526b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-be43c31 elementor-widget elementor-widget-heading\" data-id=\"be43c31\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\"><a href=\"#essais\">Essais cliniques, Publications scientifiques<\/a><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-cf74130 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"cf74130\" data-element_type=\"section\" data-e-type=\"section\" id=\"pathologie\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-c5b16bf\" data-id=\"c5b16bf\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-dbd929a elementor-widget elementor-widget-heading\" data-id=\"dbd929a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">GvHD : Pathologie et \u00e9pid\u00e9miologie\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f924f1c elementor-widget elementor-widget-text-editor\" data-id=\"f924f1c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_wrapper\"><p>La maladie du greffon contre l&rsquo;h\u00f4te (GvHD) est l&rsquo;une des complications potentielles apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (HSCT). On estime que <strong>30 \u00e0 50 % des patients d\u00e9veloppent une GvHD<\/strong> apr\u00e8s une GCSH allog\u00e9nique.<\/p><p>Il existe <strong>deux types de GvHD<\/strong>, qui se distinguent notamment par le d\u00e9lai d&rsquo;apparition des sympt\u00f4mes : les sympt\u00f4mes survenant dans les 100 jours suivant la transplantation sont class\u00e9s comme GvHD aigu\u00eb, tandis que ceux apparaissant plus tard sont consid\u00e9r\u00e9s comme GvHD chronique. Les <strong>sympt\u00f4mes<\/strong> diff\u00e8rent \u00e9galement entre ces deux formes.<\/p><ul><li>La <strong>GvHD chronique<\/strong> pr\u00e9sente des sympt\u00f4mes plus diffus. Elle peut affecter la peau, les yeux, la bouche, les muscles et le tractus gastro-intestinal, et peut entra\u00eener des infections et des difficult\u00e9s respiratoires.<\/li><li>La <strong>GvHD aigu\u00eb<\/strong>, quant \u00e0 elle, cible principalement trois organes : la peau, le foie et le tractus gastro-intestinal. La GvHD aigu\u00eb peut \u00eatre grave et rapidement fatale. C&rsquo;est l&rsquo;une des complications les plus redout\u00e9es apr\u00e8s une TCSH allog\u00e9nique et son pronostic est g\u00e9n\u00e9ralement plus sombre.<\/li><\/ul><p>Lors d&rsquo;une allo-CSH, malgr\u00e9 une s\u00e9lection rigoureuse du donneur bas\u00e9e sur la compatibilit\u00e9 HLA, le greffon peut attaquer les tissus du patient, les reconnaissant comme \u00e9trangers.<\/p><p><strong>La gravit\u00e9 de la GvHD est \u00e9valu\u00e9e sur une \u00e9chelle allant de 0 (pas de r\u00e9action) \u00e0 4 (r\u00e9action s\u00e9v\u00e8re) :<\/strong><\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-61f0f48 elementor-widget elementor-widget-image\" data-id=\"61f0f48\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"363\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png\" class=\"attachment-large size-large wp-image-16095\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-300x136.png 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-768x348.png 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1536x697.png 1536w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-2048x929.png 2048w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-69e4e4c\" data-id=\"69e4e4c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8ff7226 elementor-widget elementor-widget-text-editor\" data-id=\"8ff7226\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u00a0<\/p><p>\u00a0<\/p><p>\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f7176e4 elementor-widget elementor-widget-image\" data-id=\"f7176e4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/04\/aGvHD-Infography-2026-Abedin-V3.pdf\" target=\"_blank\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"793\" height=\"505\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/04\/aGvHD-Infography-site-internet.jpg\" class=\"attachment-2048x2048 size-2048x2048 wp-image-25462\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/04\/aGvHD-Infography-site-internet.jpg 793w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/04\/aGvHD-Infography-site-internet-300x191.jpg 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/04\/aGvHD-Infography-site-internet-768x489.jpg 768w\" sizes=\"(max-width: 793px) 100vw, 793px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d60da57 elementor-widget elementor-widget-text-editor\" data-id=\"d60da57\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_wrapper\"><p><span style=\"text-decoration: underline;\"><span style=\"color: #004e98; text-decoration: underline;\"><strong><a style=\"color: #004e98; text-decoration: underline;\" href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/04\/aGvHD-Infography-2026-Abedin-V3.pdf\" target=\"_blank\" rel=\"noopener\">Maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te \u2013 Infographie<\/a><\/strong><a style=\"color: #004e98; text-decoration: underline;\" href=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2026\/02\/aGvHD-Infography-2026-Abedin-V3.pdf\">\u00a0<strong><img decoding=\"async\" class=\"emoji aligncenter\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/16.0.1\/svg\/1f517.svg\" alt=\"\ud83d\udd17\" \/><\/strong><\/a><\/span><\/span><\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-64d8911 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"64d8911\" data-element_type=\"section\" data-e-type=\"section\" id=\"microbiote\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-626bbf1\" data-id=\"626bbf1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f192858 elementor-widget elementor-widget-heading\" data-id=\"f192858\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Le microbiote intestinal : une voie innovante dans la prise en charge des cancers du sang<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bf5faf2 elementor-widget elementor-widget-text-editor\" data-id=\"bf5faf2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Dans les h\u00e9mopathies malignes, le microbiome intestinal joue un r\u00f4le crucial dans la modulation de la r\u00e9ponse immunitaire et l&rsquo;am\u00e9lioration de l&rsquo;efficacit\u00e9 du traitement. La dysbiose caus\u00e9e par le cancer lui-m\u00eame, la chimioth\u00e9rapie ou les antibiotiques peut d\u00e9clencher une inflammation syst\u00e9mique et avoir un impact sur les r\u00e9sultats des patients. De nouvelles donn\u00e9es montrent que la restauration du microbiote peut am\u00e9liorer la tol\u00e9rance au traitement, r\u00e9duire le risque de complications telles que la maladie du greffon contre l&rsquo;h\u00f4te (GvHD) apr\u00e8s une transplantation de cellules souches allog\u00e9niques, et potentiellement prolonger la survie globale. Ces avanc\u00e9es ouvrent la voie \u00e0 de nouvelles strat\u00e9gies th\u00e9rapeutiques bas\u00e9es sur le microbiome en h\u00e9mato-oncologie.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-935d9fa elementor-widget elementor-widget-elementskit-accordion\" data-id=\"935d9fa\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"elementskit-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ekit-wid-con\" >\n        <div class=\"elementskit-accordion accoedion-primary\" id=\"accordion-69e72fadddd13\">\n\n            \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-0-935d9fa\">\n                        <a href=\"#collapse-505db0d69e72fadddd13\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-505db0d69e72fadddd13\" aria-expanded=\"false\" aria-controls=\"Collapse-505db0d69e72fadddd13\">\n                            \n                            <span class=\"ekit-accordion-title\">En savoir plus \ud83d\udc47<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"lnr lnr-plus-circle\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\" icon_minus_alt2\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-505db0d69e72fadddd13\" class=\" collapse\" aria-labelledby=\"primaryHeading-0-935d9fa\" data-parent=\"#accordion-69e72fadddd13\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <div class=\"wpb_wrapper\">\n<ul>\n \t<li><strong><em>Malard et.al, 2022 \u2013<\/em><\/strong> <a style=\"color:#5BC0CC\" href=\"\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026(22)00223-X\/fulltext\" target=\"_blank\" rel=\"noopener\"><em>Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice<\/em><\/a><em> (The Lancet Haematology)<\/em><\/li>\n \t<li><em><strong>Chang, C. C., Hayase, E., &amp; Jenq, R. R. 2021.<\/strong> <a style=\"color:#5BC0CC\" href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1872541\" target=\"_blank\" rel=\"noopener\">The role of microbiota in allogeneic hematopoietic stem cell transplantation<\/a> (Expert Opinion on Biological Therapy)<\/em><\/li>\n \t<li><strong><em>Peled et al., 2020<\/em><\/strong><em> \u2014 <a style=\"color:#5BC0CC\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1900623\" target=\"_blank\" rel=\"noopener\">Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation<\/a>\u00a0(New England Journal of Medicine)<\/em><\/li>\n \t<li><strong><em>Galloway-Pe\u00f1a et al., 2019<\/em><\/strong><em> \u2014 \u201c<a style=\"color:#5BC0CC\" href=\"https:\/\/academic.oup.com\/ofid\/article\/6\/5\/ofz173\/5427365?login=false\" target=\"_blank\" rel=\"noopener\">Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study<\/a>\u201d (Open Forum Infectious Diseases)<\/em><\/li>\n \t<li><strong><em>Kakihana et al., 2016<\/em><\/strong><em> \u2014 \u201c<a style=\"color:#5BC0CC\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27461930\/\" target=\"_blank\" rel=\"noopener\">Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut<\/a>\u201d (Blood)<\/em><\/li>\n \t<li><strong><em>Shono et al., 2016<\/em><\/strong><em><em> \u2014 <a style=\"color:#5BC0CC\" href=\"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.aaf2311\" target=\"_blank\" rel=\"noopener\"><em>Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice <\/em><\/a><\/em><\/em><em>(Science Translational Medicine)<\/em><\/li>\n \t<li><strong><em>Jenq et al., 2015<\/em><\/strong><em> \u2014 \u201c<a style=\"color:#5BC0CC\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25977230\/\" target=\"_blank\" rel=\"noopener\">Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease<\/a>\u201d (Biology of Blood and Marrow Transplantation)<\/em><\/li>\n<\/ul>\n<\/div>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                                        <\/div>\n    <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-5702432f e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-parent\" data-id=\"5702432f\" data-element_type=\"container\" data-e-type=\"container\" id=\"expert-insights\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6a009b65 elementor-widget__width-initial elementor-widget elementor-widget-video\" data-id=\"6a009b65\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;youtube_url&quot;:&quot;https:\\\/\\\/www.youtube.com\\\/watch?v=geuKnRkaM10&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<div class=\"elementor-video\"><\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2e52bdd4 elementor-widget elementor-widget-heading\" data-id=\"2e52bdd4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h5 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.youtube.com\/watch?v=geuKnRkaM10\" target=\"_blank\">Avis d\u2019expert sur l\u2019aGvH : impact sur le microbiote et approches th\u00e9rapeutiques \u2013 Pr Florent Malard<\/a><\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e8dd942 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"e8dd942\" data-element_type=\"section\" data-e-type=\"section\" id=\"EAP\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6c31da3\" data-id=\"6c31da3\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-bb64547 elementor-widget elementor-widget-heading\" data-id=\"bb64547\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Programme d\u2019acc\u00e8s compassionnel\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4d8abb3 elementor-widget elementor-widget-text-editor\" data-id=\"4d8abb3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_wrapper\"><p>Les \u00e9tudes cliniques sont cruciales pour d\u00e9montrer la s\u00e9curit\u00e9 et l\u2019efficacit\u00e9 des nouveaux traitements, permettant aux autorit\u00e9s r\u00e9glementaires d\u2019autoriser leur mise sur le march\u00e9. Toutefois, lorsqu\u2019aucune alternative th\u00e9rapeutique n\u2019existe pour des patients aux besoins importants, des m\u00e9canismes locaux permettent un acc\u00e8s pr\u00e9coce aux m\u00e9dicaments avant leur autorisation officielle, sous conditions strictes et en accord avec les autorit\u00e9s comp\u00e9tentes. <strong>L\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) octroy\u00e9e par l\u2019ANSM est une proc\u00e9dure permettant l\u2019utilisation, \u00e0 titre exceptionnel, d\u2019un m\u00e9dicament dans une indication pr\u00e9cise en l\u2019absence de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) ou avant la d\u00e9livrance d\u2019une telle AMM pour ce m\u00e9dicament<\/strong>.<br \/>Toutes les conditions suivantes sont \u00e0 remplir pour r\u00e9aliser une demande :<\/p><ul><li>Le m\u00e9dicament est destin\u00e9 \u00e0 traiter une maladie grave, rare ou invalidante,<\/li><li>Il n\u2019existe pas de traitement appropri\u00e9,<\/li><li>Le m\u00e9dicament ne fait pas l\u2019objet d\u2019une recherche impliquant la personne humaine (RIPH) \u00e0 des fins commerciales,<\/li><li>ou,\u00a0 lorsque le m\u00e9dicament fait l\u2019objet d\u2019une RIPH \u00e0 des fins commerciales, le patient ne peut participer \u00e0 cette recherche, \u00a0la mise en \u0153uvre du traitement ne peut pas \u00eatre diff\u00e9r\u00e9e, \u00a0et le laboratoire s\u2019est engag\u00e9 \u00e0 d\u00e9poser une demande d\u2019acc\u00e8s pr\u00e9coce,<\/li><li>L\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du m\u00e9dicament sont pr\u00e9sum\u00e9es\u00a0au regard des donn\u00e9es cliniques disponibles.<\/li><\/ul><p>MaaT Pharma collabore \u00e9troitement avec l\u2019ANSM pour le suivi des patients b\u00e9n\u00e9ficiant d\u2019un acc\u00e8s compassionnel selon les modalit\u00e9s fix\u00e9es dans le Protocole d\u2019Utilisation Th\u00e9rapeutique et de Suivi des Patients (PUT-SP) le cas \u00e9ch\u00e9ant. Le r\u00e9f\u00e9rentiel des acc\u00e8s compassionnels en cours est disponible sur le <a href=\"https:\/\/ansm.sante.fr\/documents\/reference\/referentiel-des-specialites-en-acces-derogatoire\" target=\"_blank\" rel=\"noopener\">site de l\u2019ANSM<\/a>. Toute demande pour faire b\u00e9n\u00e9ficier un patient d\u2019un acc\u00e8s compassionnel en cours se fait via le site de l\u2019ANSM \u00ab e-Saturne \u00bb.<\/p><p>Pour toute question relative au programme d\u2019acc\u00e8s compassionnel, vous pouvez nous <a href=\"https:\/\/www.maatpharma.com\/fr\/contact\/\">contacter<\/a>.<\/p><p><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/12\/Notice_Medecins_Pharmaciens_ACTP_MaaT013.pdf\"><strong>Notice d\u2019Information \u2013 Professionnels de Sant\u00e9 \u2013 <\/strong><strong>Programme d\u2019Acc\u00e8s Compassionnel Tr\u00e8s Pr\u00e9coce (ACTP \/ ECAP) \u2013 MaaT013<\/strong><\/a><\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-0a31b97 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"0a31b97\" data-element_type=\"section\" data-e-type=\"section\" id=\"essais\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ba20e49\" data-id=\"ba20e49\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1443d74 elementor-widget elementor-widget-heading\" data-id=\"1443d74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Essais cliniques, donn\u00e9es cliniques et publications scientifiques<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8dfbbd2 elementor-widget elementor-widget-n-accordion\" data-id=\"8dfbbd2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1480\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1480\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Essais Cliniques <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"lnr lnr-circle-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"lnr lnr-plus-circle\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1480\" class=\"elementor-element elementor-element-b6e82f5 e-con-full e-flex wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-child\" data-id=\"b6e82f5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1480\" class=\"elementor-element elementor-element-55e33e8 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-child\" data-id=\"55e33e8\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-922ec8e elementor-widget elementor-widget-text-editor\" data-id=\"922ec8e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_wrapper\"><ul><li><strong>MaaT013 \u2013 Essai clinique de phase III \u2013 ARES: <\/strong><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04769895\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT04769895<\/a><\/li><\/ul><ul><li><strong>MaaT033 \u2013 Essai clinique de phase II \u2013 PHOEBUS: <\/strong><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05762211\" target=\"_blank\" rel=\"noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05762211<\/a><\/li><\/ul><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1481\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1481\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Donn\u00e9es Cliniques <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"lnr lnr-circle-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"lnr lnr-plus-circle\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1481\" class=\"elementor-element elementor-element-2f21bd3 e-con-full e-flex wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-child\" data-id=\"2f21bd3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9374c27 elementor-widget elementor-widget-text-editor\" data-id=\"9374c27\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"inner-toggle-wrap\"><div class=\"wpb_text_column wpb_content_element \"><div class=\"wpb_wrapper\"><p><strong>R\u00e9sultats Principaux Phase III\u00a0 Pivotale (MaaT013): ARES<\/strong><\/p><ul><li><a href=\"https:\/\/www.maatpharma.com\/fr\/phase-3\/\">MaaT Pharma \u2013 R\u00e9sultats de la Phase II ARES<\/a><\/li><li>OncLive: <a href=\"https:\/\/www.onclive.com\/view\/ares-trial-of-maat013-in-gi-agvhd-meets-primary-end-point-of-gi-orr\" target=\"_blank\" rel=\"noopener\">ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR<\/a><\/li><\/ul><\/div><\/div><div class=\"wpb_text_column wpb_content_element \"><div class=\"wpb_wrapper\"><p>\u00a0<\/p><p><strong>Programme d\u2019acc\u00e8s compassionnel<\/strong><\/p><ul><li>Donn\u00e9es pr\u00e9sent\u00e9es au <a href=\"https:\/\/www.maatpharma.com\/fr\/pooled-fecal-allogenic-microbiotherapy-for-refractory-gastrointestinal-acute-graft-versus-host-disease-results-from-early-access-program-in-europe\/\" target=\"_blank\" rel=\"noopener\">congr\u00e8s de l\u2019ASH en d\u00e9cembre 202<\/a>4 et au <a href=\"https:\/\/www.maatpharma.com\/fr\/13-juin-2025-maat-pharma-presente-des-donnees-actualisees-positives-pour-le-programme-dacces-compassionnel-pour-xervyteg-lors-du-congres-de-leha-confirmant-une-forte-efficaci\/\" target=\"_blank\" rel=\"noopener\">Congr\u00e8s de l\u2019EHA en juin 2025<\/a><\/li><li>En savoir plus sur l\u2019Acc\u00e8s d\u00e9rogatoire en France \u2013 <a href=\"https:\/\/ansm.sante.fr\/tableau-acces-derogatoire\/maat013\" target=\"_blank\" rel=\"noopener\">Lien vers le site internet de l\u2019ANSM<\/a><\/li><\/ul><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1482\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1482\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Publications Scientifiques <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"lnr lnr-circle-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"lnr lnr-plus-circle\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1482\" class=\"elementor-element elementor-element-2c0d423 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-child\" data-id=\"2c0d423\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2b73e74 elementor-widget elementor-widget-text-editor\" data-id=\"2b73e74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_wrapper\"><p><strong>Management de l\u2019aGvH<\/strong><\/p><ul><li><em><strong>Abedin et al., 2021 \u2013<\/strong>\u00a0 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34254289\/\" target=\"_blank\" rel=\"noopener\">Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease \u2013 a real-world outcomes analysis<\/a> (British Journal of Haematology)<\/em><\/li><li><em><strong>Penack O et al.,2021 \u2013 <\/strong>\u00a0<a href=\"https:\/\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026(23)00342-3\/abstract\" target=\"_blank\" rel=\"noopener\">Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation<\/a> (The Lancet Haematology)<\/em><\/li><li><em><strong><span class=\"author\">Martin PJ<\/span>,\u00a0<span class=\"author\">Rizzo JD<\/span>,\u00a0<span class=\"author\">Wingard JR<\/span>,\u00a0<span class=\"author\">Ballen K<\/span>,\u00a0<span class=\"author\">Curtin PT<\/span>,\u00a0<span class=\"author\">Cutler C<\/span>, et al.(2012)<\/strong> \u2013\u00a0<\/em> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1083879112001449?pes=vor&amp;utm_source=wiley&amp;getft_integrator=wiley\" target=\"_blank\" rel=\"noopener\"><span class=\"articleTitle\">First and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American society of blood and marrow transplantation<\/span>.<\/a> (<i>Biol Blood Marrow Transplant)<\/i><\/li><li><em><strong>Ferrara JL et al., 2009<\/strong> \u2013 <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(09)60237-3\/abstract\" target=\"_blank\" rel=\"noopener\">Graft-versus-host disease<\/a> (The Lancet)\u00a0<\/em><\/li><\/ul><p><strong>Microbiote intestinal &amp; GvH<\/strong><\/p><ul><li><em><strong>Malard F et al. (2023) \u2013 <\/strong><a href=\"https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(23)00288-2\/fulltext\" target=\"_blank\" rel=\"noopener\">Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. <\/a>(eClinicalMedicine)<\/em><\/li><li><em><strong>Malard F. et al. (2021) \u2013<\/strong>\u00a0<a href=\"https:\/\/www.nature.com\/articles\/s41467-021-23376-6\" target=\"_blank\" rel=\"noopener\">Restoration of gut microbiota diversity with autologous fecal microbiota transfer in acute myeloid leukemia patients. <\/a>(Nature communications)\u00a0<\/em><\/li><li><em><strong>Malard F.\u00a0et al. (2018) \u2013<\/strong> <a href=\"https:\/\/www.nature.com\/articles\/s41409-018-0254-x\" target=\"_blank\" rel=\"noopener\">High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients\u00a0 <\/a>(Bone Marrow Transplantation)<\/em><\/li><\/ul><p><strong>Production &amp; Process\u00a0<\/strong><\/p><ul><li><em><strong>Gefen, R., Dourado, J., Emile, S.H.\u00a0et al.(2025) \u2013\u00a0\u00a0<\/strong><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s10151-025-03113-7#citeas\" target=\"_blank\" rel=\"noopener\">Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials.\u00a0Techniques in Coloproctology<\/a>\u00a0\u2013 Springer Nature\u00a0<\/em><\/li><li><em><strong>Reygner.et al. (2024) \u2013 <\/strong><a href=\"https:\/\/journals.asm.org\/doi\/10.1128\/aem.00016-24\" target=\"_blank\" rel=\"noopener\">Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models <\/a>(Applied and Environmental Microbiology \u2013\u00a0ASM Journals)<\/em><\/li><li><em><strong>Laperrousaz B.\u00a0et al (2024) \u2013<\/strong> <a href=\"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03487-2#citeas\" target=\"_blank\" rel=\"noopener\">Safety comparison of single-donor and pooled fecal microbiota transfer product preparation in ulcerative colitis: systematic review and meta-analysis.<\/a> (BMC Gastroenterology)<\/em><\/li><\/ul><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Professionnels de la sant\u00e9 Cette page est destin\u00e9e aux professionnels de la sant\u00e9. &#x27a1; Revenir \u00e0 Patients et Professionnels de sant\u00e9 GvHD : Pathologie et \u00e9pid\u00e9miologie Microbiome intestinal et cancers du sang Programme d&rsquo;acc\u00e8s anticip\u00e9 Essais cliniques, Publications scientifiques GvHD : Pathologie et \u00e9pid\u00e9miologie La maladie du greffon contre l&rsquo;h\u00f4te (GvHD) est l&rsquo;une des complications potentielles apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (HSCT). On estime que 30 \u00e0 50 % des patients d\u00e9veloppent une GvHD apr\u00e8s une GCSH allog\u00e9nique. Il existe deux types de GvHD, qui se distinguent notamment par le d\u00e9lai d&rsquo;apparition des sympt\u00f4mes : les sympt\u00f4mes survenant dans les 100 jours suivant la transplantation sont class\u00e9s comme GvHD aigu\u00eb, tandis que ceux apparaissant plus tard sont consid\u00e9r\u00e9s comme GvHD chronique. Les sympt\u00f4mes diff\u00e8rent \u00e9galement entre ces deux formes. La GvHD chronique pr\u00e9sente des sympt\u00f4mes plus diffus. Elle peut affecter la peau, les yeux, la bouche, les muscles et le tractus gastro-intestinal, et peut entra\u00eener des infections et des difficult\u00e9s respiratoires. La GvHD aigu\u00eb, quant \u00e0 elle, cible principalement trois organes : la peau, le foie et le tractus gastro-intestinal. La GvHD aigu\u00eb peut \u00eatre grave et rapidement fatale. C&rsquo;est l&rsquo;une des complications les plus redout\u00e9es apr\u00e8s une TCSH allog\u00e9nique et son pronostic est g\u00e9n\u00e9ralement plus sombre. Lors d&rsquo;une allo-CSH, malgr\u00e9 une s\u00e9lection rigoureuse du donneur bas\u00e9e sur la compatibilit\u00e9 HLA, le greffon peut attaquer les tissus du patient, les reconnaissant comme \u00e9trangers. La gravit\u00e9 de la GvHD est \u00e9valu\u00e9e sur une \u00e9chelle allant de 0 (pas de r\u00e9action) \u00e0 4 (r\u00e9action s\u00e9v\u00e8re) : \u00a0 \u00a0 \u00a0 Maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te \u2013 Infographie\u00a0 Le microbiote intestinal : une voie innovante dans la prise en charge des cancers du sang Dans les h\u00e9mopathies malignes, le microbiome intestinal joue un r\u00f4le crucial dans la modulation de la r\u00e9ponse immunitaire et l&rsquo;am\u00e9lioration de l&rsquo;efficacit\u00e9 du traitement. La dysbiose caus\u00e9e par le cancer lui-m\u00eame, la chimioth\u00e9rapie ou les antibiotiques peut d\u00e9clencher une inflammation syst\u00e9mique et avoir un impact sur les r\u00e9sultats des patients. De nouvelles donn\u00e9es montrent que la restauration du microbiote peut am\u00e9liorer la tol\u00e9rance au traitement, r\u00e9duire le risque de complications telles que la maladie du greffon contre l&rsquo;h\u00f4te (GvHD) apr\u00e8s une transplantation de cellules souches allog\u00e9niques, et potentiellement prolonger la survie globale. Ces avanc\u00e9es ouvrent la voie \u00e0 de nouvelles strat\u00e9gies th\u00e9rapeutiques bas\u00e9es sur le microbiome en h\u00e9mato-oncologie. En savoir plus &#x1f447; Malard et.al, 2022 \u2013 Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice (The Lancet Haematology) Chang, C. C., Hayase, E., &amp; Jenq, R. R. 2021. The role of microbiota in allogeneic hematopoietic stem cell transplantation (Expert Opinion on Biological Therapy) Peled et al., 2020 \u2014 Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation\u00a0(New England Journal of Medicine) Galloway-Pe\u00f1a et al., 2019 \u2014 \u201cFecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study\u201d (Open Forum Infectious Diseases) Kakihana et al., 2016 \u2014 \u201cFecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut\u201d (Blood) Shono et al., 2016 \u2014 Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice (Science Translational Medicine) Jenq et al., 2015 \u2014 \u201cIntestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease\u201d (Biology of Blood and Marrow Transplantation) Avis d\u2019expert sur l\u2019aGvH : impact sur le microbiote et approches th\u00e9rapeutiques \u2013 Pr Florent Malard Programme d\u2019acc\u00e8s compassionnel Les \u00e9tudes cliniques sont cruciales pour d\u00e9montrer la s\u00e9curit\u00e9 et l\u2019efficacit\u00e9 des nouveaux traitements, permettant aux autorit\u00e9s r\u00e9glementaires d\u2019autoriser leur mise sur le march\u00e9. Toutefois, lorsqu\u2019aucune alternative th\u00e9rapeutique n\u2019existe pour des patients aux besoins importants, des m\u00e9canismes locaux permettent un acc\u00e8s pr\u00e9coce aux m\u00e9dicaments avant leur autorisation officielle, sous conditions strictes et en accord avec les autorit\u00e9s comp\u00e9tentes. L\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) octroy\u00e9e par l\u2019ANSM est une proc\u00e9dure permettant l\u2019utilisation, \u00e0 titre exceptionnel, d\u2019un m\u00e9dicament dans une indication pr\u00e9cise en l\u2019absence de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) ou avant la d\u00e9livrance d\u2019une telle AMM pour ce m\u00e9dicament.Toutes les conditions suivantes sont \u00e0 remplir pour r\u00e9aliser une demande : Le m\u00e9dicament est destin\u00e9 \u00e0 traiter une maladie grave, rare ou invalidante, Il n\u2019existe pas de traitement appropri\u00e9, Le m\u00e9dicament ne fait pas l\u2019objet d\u2019une recherche impliquant la personne humaine (RIPH) \u00e0 des fins commerciales, ou,\u00a0 lorsque le m\u00e9dicament fait l\u2019objet d\u2019une RIPH \u00e0 des fins commerciales, le patient ne peut participer \u00e0 cette recherche, \u00a0la mise en \u0153uvre du traitement ne peut pas \u00eatre diff\u00e9r\u00e9e, \u00a0et le laboratoire s\u2019est engag\u00e9 \u00e0 d\u00e9poser une demande d\u2019acc\u00e8s pr\u00e9coce, L\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du m\u00e9dicament sont pr\u00e9sum\u00e9es\u00a0au regard des donn\u00e9es cliniques disponibles. MaaT Pharma collabore \u00e9troitement avec l\u2019ANSM pour le suivi des patients b\u00e9n\u00e9ficiant d\u2019un acc\u00e8s compassionnel selon les modalit\u00e9s fix\u00e9es dans le Protocole d\u2019Utilisation Th\u00e9rapeutique et de Suivi des Patients (PUT-SP) le cas \u00e9ch\u00e9ant. Le r\u00e9f\u00e9rentiel des acc\u00e8s compassionnels en cours est disponible sur le site de l\u2019ANSM. Toute demande pour faire b\u00e9n\u00e9ficier un patient d\u2019un acc\u00e8s compassionnel en cours se fait via le site de l\u2019ANSM \u00ab e-Saturne \u00bb. Pour toute question relative au programme d\u2019acc\u00e8s compassionnel, vous pouvez nous contacter. Notice d\u2019Information \u2013 Professionnels de Sant\u00e9 \u2013 Programme d\u2019Acc\u00e8s Compassionnel Tr\u00e8s Pr\u00e9coce (ACTP \/ ECAP) \u2013 MaaT013 Essais cliniques, donn\u00e9es cliniques et publications scientifiques Essais Cliniques MaaT013 \u2013 Essai clinique de phase III \u2013 ARES: https:\/\/clinicaltrials.gov\/study\/NCT04769895 MaaT033 \u2013 Essai clinique de phase II \u2013 PHOEBUS: https:\/\/clinicaltrials.gov\/study\/NCT05762211 Donn\u00e9es Cliniques R\u00e9sultats Principaux Phase III\u00a0 Pivotale (MaaT013): ARES MaaT Pharma \u2013 R\u00e9sultats de la Phase II ARES OncLive: ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR \u00a0 Programme d\u2019acc\u00e8s compassionnel Donn\u00e9es pr\u00e9sent\u00e9es au congr\u00e8s de l\u2019ASH en d\u00e9cembre 2024 et au Congr\u00e8s de l\u2019EHA en juin 2025 En savoir plus sur l\u2019Acc\u00e8s d\u00e9rogatoire en France \u2013 Lien vers le site internet de l\u2019ANSM Publications Scientifiques Management de l\u2019aGvH Abedin et al., 2021 \u2013\u00a0 Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease \u2013 a real-world outcomes analysis (British Journal of Haematology) Penack O et al.,2021 \u2013<\/p>\n","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-21319","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Professionnels de la sant\u00e9 - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Professionnels de la sant\u00e9 - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"Professionnels de la sant\u00e9 Cette page est destin\u00e9e aux professionnels de la sant\u00e9. &#x27a1; Revenir \u00e0 Patients et Professionnels de sant\u00e9 GvHD : Pathologie et \u00e9pid\u00e9miologie Microbiome intestinal et cancers du sang Programme d&rsquo;acc\u00e8s anticip\u00e9 Essais cliniques, Publications scientifiques GvHD : Pathologie et \u00e9pid\u00e9miologie La maladie du greffon contre l&rsquo;h\u00f4te (GvHD) est l&rsquo;une des complications potentielles apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (HSCT). On estime que 30 \u00e0 50 % des patients d\u00e9veloppent une GvHD apr\u00e8s une GCSH allog\u00e9nique. Il existe deux types de GvHD, qui se distinguent notamment par le d\u00e9lai d&rsquo;apparition des sympt\u00f4mes : les sympt\u00f4mes survenant dans les 100 jours suivant la transplantation sont class\u00e9s comme GvHD aigu\u00eb, tandis que ceux apparaissant plus tard sont consid\u00e9r\u00e9s comme GvHD chronique. Les sympt\u00f4mes diff\u00e8rent \u00e9galement entre ces deux formes. La GvHD chronique pr\u00e9sente des sympt\u00f4mes plus diffus. Elle peut affecter la peau, les yeux, la bouche, les muscles et le tractus gastro-intestinal, et peut entra\u00eener des infections et des difficult\u00e9s respiratoires. La GvHD aigu\u00eb, quant \u00e0 elle, cible principalement trois organes : la peau, le foie et le tractus gastro-intestinal. La GvHD aigu\u00eb peut \u00eatre grave et rapidement fatale. C&rsquo;est l&rsquo;une des complications les plus redout\u00e9es apr\u00e8s une TCSH allog\u00e9nique et son pronostic est g\u00e9n\u00e9ralement plus sombre. Lors d&rsquo;une allo-CSH, malgr\u00e9 une s\u00e9lection rigoureuse du donneur bas\u00e9e sur la compatibilit\u00e9 HLA, le greffon peut attaquer les tissus du patient, les reconnaissant comme \u00e9trangers. La gravit\u00e9 de la GvHD est \u00e9valu\u00e9e sur une \u00e9chelle allant de 0 (pas de r\u00e9action) \u00e0 4 (r\u00e9action s\u00e9v\u00e8re) : \u00a0 \u00a0 \u00a0 Maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te \u2013 Infographie\u00a0 Le microbiote intestinal : une voie innovante dans la prise en charge des cancers du sang Dans les h\u00e9mopathies malignes, le microbiome intestinal joue un r\u00f4le crucial dans la modulation de la r\u00e9ponse immunitaire et l&rsquo;am\u00e9lioration de l&rsquo;efficacit\u00e9 du traitement. La dysbiose caus\u00e9e par le cancer lui-m\u00eame, la chimioth\u00e9rapie ou les antibiotiques peut d\u00e9clencher une inflammation syst\u00e9mique et avoir un impact sur les r\u00e9sultats des patients. De nouvelles donn\u00e9es montrent que la restauration du microbiote peut am\u00e9liorer la tol\u00e9rance au traitement, r\u00e9duire le risque de complications telles que la maladie du greffon contre l&rsquo;h\u00f4te (GvHD) apr\u00e8s une transplantation de cellules souches allog\u00e9niques, et potentiellement prolonger la survie globale. Ces avanc\u00e9es ouvrent la voie \u00e0 de nouvelles strat\u00e9gies th\u00e9rapeutiques bas\u00e9es sur le microbiome en h\u00e9mato-oncologie. En savoir plus &#x1f447; Malard et.al, 2022 \u2013 Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice (The Lancet Haematology) Chang, C. C., Hayase, E., &amp; Jenq, R. R. 2021. The role of microbiota in allogeneic hematopoietic stem cell transplantation (Expert Opinion on Biological Therapy) Peled et al., 2020 \u2014 Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation\u00a0(New England Journal of Medicine) Galloway-Pe\u00f1a et al., 2019 \u2014 \u201cFecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study\u201d (Open Forum Infectious Diseases) Kakihana et al., 2016 \u2014 \u201cFecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut\u201d (Blood) Shono et al., 2016 \u2014 Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice (Science Translational Medicine) Jenq et al., 2015 \u2014 \u201cIntestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease\u201d (Biology of Blood and Marrow Transplantation) Avis d\u2019expert sur l\u2019aGvH : impact sur le microbiote et approches th\u00e9rapeutiques \u2013 Pr Florent Malard Programme d\u2019acc\u00e8s compassionnel Les \u00e9tudes cliniques sont cruciales pour d\u00e9montrer la s\u00e9curit\u00e9 et l\u2019efficacit\u00e9 des nouveaux traitements, permettant aux autorit\u00e9s r\u00e9glementaires d\u2019autoriser leur mise sur le march\u00e9. Toutefois, lorsqu\u2019aucune alternative th\u00e9rapeutique n\u2019existe pour des patients aux besoins importants, des m\u00e9canismes locaux permettent un acc\u00e8s pr\u00e9coce aux m\u00e9dicaments avant leur autorisation officielle, sous conditions strictes et en accord avec les autorit\u00e9s comp\u00e9tentes. L\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) octroy\u00e9e par l\u2019ANSM est une proc\u00e9dure permettant l\u2019utilisation, \u00e0 titre exceptionnel, d\u2019un m\u00e9dicament dans une indication pr\u00e9cise en l\u2019absence de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) ou avant la d\u00e9livrance d\u2019une telle AMM pour ce m\u00e9dicament.Toutes les conditions suivantes sont \u00e0 remplir pour r\u00e9aliser une demande : Le m\u00e9dicament est destin\u00e9 \u00e0 traiter une maladie grave, rare ou invalidante, Il n\u2019existe pas de traitement appropri\u00e9, Le m\u00e9dicament ne fait pas l\u2019objet d\u2019une recherche impliquant la personne humaine (RIPH) \u00e0 des fins commerciales, ou,\u00a0 lorsque le m\u00e9dicament fait l\u2019objet d\u2019une RIPH \u00e0 des fins commerciales, le patient ne peut participer \u00e0 cette recherche, \u00a0la mise en \u0153uvre du traitement ne peut pas \u00eatre diff\u00e9r\u00e9e, \u00a0et le laboratoire s\u2019est engag\u00e9 \u00e0 d\u00e9poser une demande d\u2019acc\u00e8s pr\u00e9coce, L\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du m\u00e9dicament sont pr\u00e9sum\u00e9es\u00a0au regard des donn\u00e9es cliniques disponibles. MaaT Pharma collabore \u00e9troitement avec l\u2019ANSM pour le suivi des patients b\u00e9n\u00e9ficiant d\u2019un acc\u00e8s compassionnel selon les modalit\u00e9s fix\u00e9es dans le Protocole d\u2019Utilisation Th\u00e9rapeutique et de Suivi des Patients (PUT-SP) le cas \u00e9ch\u00e9ant. Le r\u00e9f\u00e9rentiel des acc\u00e8s compassionnels en cours est disponible sur le site de l\u2019ANSM. Toute demande pour faire b\u00e9n\u00e9ficier un patient d\u2019un acc\u00e8s compassionnel en cours se fait via le site de l\u2019ANSM \u00ab e-Saturne \u00bb. Pour toute question relative au programme d\u2019acc\u00e8s compassionnel, vous pouvez nous contacter. Notice d\u2019Information \u2013 Professionnels de Sant\u00e9 \u2013 Programme d\u2019Acc\u00e8s Compassionnel Tr\u00e8s Pr\u00e9coce (ACTP \/ ECAP) \u2013 MaaT013 Essais cliniques, donn\u00e9es cliniques et publications scientifiques Essais Cliniques MaaT013 \u2013 Essai clinique de phase III \u2013 ARES: https:\/\/clinicaltrials.gov\/study\/NCT04769895 MaaT033 \u2013 Essai clinique de phase II \u2013 PHOEBUS: https:\/\/clinicaltrials.gov\/study\/NCT05762211 Donn\u00e9es Cliniques R\u00e9sultats Principaux Phase III\u00a0 Pivotale (MaaT013): ARES MaaT Pharma \u2013 R\u00e9sultats de la Phase II ARES OncLive: ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR \u00a0 Programme d\u2019acc\u00e8s compassionnel Donn\u00e9es pr\u00e9sent\u00e9es au congr\u00e8s de l\u2019ASH en d\u00e9cembre 2024 et au Congr\u00e8s de l\u2019EHA en juin 2025 En savoir plus sur l\u2019Acc\u00e8s d\u00e9rogatoire en France \u2013 Lien vers le site internet de l\u2019ANSM Publications Scientifiques Management de l\u2019aGvH Abedin et al., 2021 \u2013\u00a0 Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease \u2013 a real-world outcomes analysis (British Journal of Haematology) Penack O et al.,2021 \u2013\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T15:23:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/\",\"name\":\"Professionnels de la sant\u00e9 - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/FR-tableau-grade-1024x465.png\",\"datePublished\":\"2026-01-02T21:06:51+00:00\",\"dateModified\":\"2026-04-07T15:23:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/FR-tableau-grade-1024x465.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/FR-tableau-grade-1024x465.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/professionnels-de-la-sante\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Professionnels de la sant\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Professionnels de la sant\u00e9 - MaaT Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/","og_locale":"fr_FR","og_type":"article","og_title":"Professionnels de la sant\u00e9 - MaaT Pharma","og_description":"Professionnels de la sant\u00e9 Cette page est destin\u00e9e aux professionnels de la sant\u00e9. &#x27a1; Revenir \u00e0 Patients et Professionnels de sant\u00e9 GvHD : Pathologie et \u00e9pid\u00e9miologie Microbiome intestinal et cancers du sang Programme d&rsquo;acc\u00e8s anticip\u00e9 Essais cliniques, Publications scientifiques GvHD : Pathologie et \u00e9pid\u00e9miologie La maladie du greffon contre l&rsquo;h\u00f4te (GvHD) est l&rsquo;une des complications potentielles apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (HSCT). On estime que 30 \u00e0 50 % des patients d\u00e9veloppent une GvHD apr\u00e8s une GCSH allog\u00e9nique. Il existe deux types de GvHD, qui se distinguent notamment par le d\u00e9lai d&rsquo;apparition des sympt\u00f4mes : les sympt\u00f4mes survenant dans les 100 jours suivant la transplantation sont class\u00e9s comme GvHD aigu\u00eb, tandis que ceux apparaissant plus tard sont consid\u00e9r\u00e9s comme GvHD chronique. Les sympt\u00f4mes diff\u00e8rent \u00e9galement entre ces deux formes. La GvHD chronique pr\u00e9sente des sympt\u00f4mes plus diffus. Elle peut affecter la peau, les yeux, la bouche, les muscles et le tractus gastro-intestinal, et peut entra\u00eener des infections et des difficult\u00e9s respiratoires. La GvHD aigu\u00eb, quant \u00e0 elle, cible principalement trois organes : la peau, le foie et le tractus gastro-intestinal. La GvHD aigu\u00eb peut \u00eatre grave et rapidement fatale. C&rsquo;est l&rsquo;une des complications les plus redout\u00e9es apr\u00e8s une TCSH allog\u00e9nique et son pronostic est g\u00e9n\u00e9ralement plus sombre. Lors d&rsquo;une allo-CSH, malgr\u00e9 une s\u00e9lection rigoureuse du donneur bas\u00e9e sur la compatibilit\u00e9 HLA, le greffon peut attaquer les tissus du patient, les reconnaissant comme \u00e9trangers. La gravit\u00e9 de la GvHD est \u00e9valu\u00e9e sur une \u00e9chelle allant de 0 (pas de r\u00e9action) \u00e0 4 (r\u00e9action s\u00e9v\u00e8re) : \u00a0 \u00a0 \u00a0 Maladie aigu\u00eb du greffon contre l&rsquo;h\u00f4te \u2013 Infographie\u00a0 Le microbiote intestinal : une voie innovante dans la prise en charge des cancers du sang Dans les h\u00e9mopathies malignes, le microbiome intestinal joue un r\u00f4le crucial dans la modulation de la r\u00e9ponse immunitaire et l&rsquo;am\u00e9lioration de l&rsquo;efficacit\u00e9 du traitement. La dysbiose caus\u00e9e par le cancer lui-m\u00eame, la chimioth\u00e9rapie ou les antibiotiques peut d\u00e9clencher une inflammation syst\u00e9mique et avoir un impact sur les r\u00e9sultats des patients. De nouvelles donn\u00e9es montrent que la restauration du microbiote peut am\u00e9liorer la tol\u00e9rance au traitement, r\u00e9duire le risque de complications telles que la maladie du greffon contre l&rsquo;h\u00f4te (GvHD) apr\u00e8s une transplantation de cellules souches allog\u00e9niques, et potentiellement prolonger la survie globale. Ces avanc\u00e9es ouvrent la voie \u00e0 de nouvelles strat\u00e9gies th\u00e9rapeutiques bas\u00e9es sur le microbiome en h\u00e9mato-oncologie. En savoir plus &#x1f447; Malard et.al, 2022 \u2013 Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice (The Lancet Haematology) Chang, C. C., Hayase, E., &amp; Jenq, R. R. 2021. The role of microbiota in allogeneic hematopoietic stem cell transplantation (Expert Opinion on Biological Therapy) Peled et al., 2020 \u2014 Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation\u00a0(New England Journal of Medicine) Galloway-Pe\u00f1a et al., 2019 \u2014 \u201cFecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study\u201d (Open Forum Infectious Diseases) Kakihana et al., 2016 \u2014 \u201cFecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut\u201d (Blood) Shono et al., 2016 \u2014 Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice (Science Translational Medicine) Jenq et al., 2015 \u2014 \u201cIntestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease\u201d (Biology of Blood and Marrow Transplantation) Avis d\u2019expert sur l\u2019aGvH : impact sur le microbiote et approches th\u00e9rapeutiques \u2013 Pr Florent Malard Programme d\u2019acc\u00e8s compassionnel Les \u00e9tudes cliniques sont cruciales pour d\u00e9montrer la s\u00e9curit\u00e9 et l\u2019efficacit\u00e9 des nouveaux traitements, permettant aux autorit\u00e9s r\u00e9glementaires d\u2019autoriser leur mise sur le march\u00e9. Toutefois, lorsqu\u2019aucune alternative th\u00e9rapeutique n\u2019existe pour des patients aux besoins importants, des m\u00e9canismes locaux permettent un acc\u00e8s pr\u00e9coce aux m\u00e9dicaments avant leur autorisation officielle, sous conditions strictes et en accord avec les autorit\u00e9s comp\u00e9tentes. L\u2019Autorisation d\u2019Acc\u00e8s Compassionnel (AAC) octroy\u00e9e par l\u2019ANSM est une proc\u00e9dure permettant l\u2019utilisation, \u00e0 titre exceptionnel, d\u2019un m\u00e9dicament dans une indication pr\u00e9cise en l\u2019absence de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) ou avant la d\u00e9livrance d\u2019une telle AMM pour ce m\u00e9dicament.Toutes les conditions suivantes sont \u00e0 remplir pour r\u00e9aliser une demande : Le m\u00e9dicament est destin\u00e9 \u00e0 traiter une maladie grave, rare ou invalidante, Il n\u2019existe pas de traitement appropri\u00e9, Le m\u00e9dicament ne fait pas l\u2019objet d\u2019une recherche impliquant la personne humaine (RIPH) \u00e0 des fins commerciales, ou,\u00a0 lorsque le m\u00e9dicament fait l\u2019objet d\u2019une RIPH \u00e0 des fins commerciales, le patient ne peut participer \u00e0 cette recherche, \u00a0la mise en \u0153uvre du traitement ne peut pas \u00eatre diff\u00e9r\u00e9e, \u00a0et le laboratoire s\u2019est engag\u00e9 \u00e0 d\u00e9poser une demande d\u2019acc\u00e8s pr\u00e9coce, L\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 du m\u00e9dicament sont pr\u00e9sum\u00e9es\u00a0au regard des donn\u00e9es cliniques disponibles. MaaT Pharma collabore \u00e9troitement avec l\u2019ANSM pour le suivi des patients b\u00e9n\u00e9ficiant d\u2019un acc\u00e8s compassionnel selon les modalit\u00e9s fix\u00e9es dans le Protocole d\u2019Utilisation Th\u00e9rapeutique et de Suivi des Patients (PUT-SP) le cas \u00e9ch\u00e9ant. Le r\u00e9f\u00e9rentiel des acc\u00e8s compassionnels en cours est disponible sur le site de l\u2019ANSM. Toute demande pour faire b\u00e9n\u00e9ficier un patient d\u2019un acc\u00e8s compassionnel en cours se fait via le site de l\u2019ANSM \u00ab e-Saturne \u00bb. Pour toute question relative au programme d\u2019acc\u00e8s compassionnel, vous pouvez nous contacter. Notice d\u2019Information \u2013 Professionnels de Sant\u00e9 \u2013 Programme d\u2019Acc\u00e8s Compassionnel Tr\u00e8s Pr\u00e9coce (ACTP \/ ECAP) \u2013 MaaT013 Essais cliniques, donn\u00e9es cliniques et publications scientifiques Essais Cliniques MaaT013 \u2013 Essai clinique de phase III \u2013 ARES: https:\/\/clinicaltrials.gov\/study\/NCT04769895 MaaT033 \u2013 Essai clinique de phase II \u2013 PHOEBUS: https:\/\/clinicaltrials.gov\/study\/NCT05762211 Donn\u00e9es Cliniques R\u00e9sultats Principaux Phase III\u00a0 Pivotale (MaaT013): ARES MaaT Pharma \u2013 R\u00e9sultats de la Phase II ARES OncLive: ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR \u00a0 Programme d\u2019acc\u00e8s compassionnel Donn\u00e9es pr\u00e9sent\u00e9es au congr\u00e8s de l\u2019ASH en d\u00e9cembre 2024 et au Congr\u00e8s de l\u2019EHA en juin 2025 En savoir plus sur l\u2019Acc\u00e8s d\u00e9rogatoire en France \u2013 Lien vers le site internet de l\u2019ANSM Publications Scientifiques Management de l\u2019aGvH Abedin et al., 2021 \u2013\u00a0 Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease \u2013 a real-world outcomes analysis (British Journal of Haematology) Penack O et al.,2021 \u2013","og_url":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/","og_site_name":"MaaT Pharma","article_modified_time":"2026-04-07T15:23:52+00:00","og_image":[{"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/","url":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/","name":"Professionnels de la sant\u00e9 - MaaT Pharma","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png","datePublished":"2026-01-02T21:06:51+00:00","dateModified":"2026-04-07T15:23:52+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/FR-tableau-grade-1024x465.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/fr\/professionnels-de-la-sante\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Professionnels de la sant\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages\/21319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=21319"}],"version-history":[{"count":23,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages\/21319\/revisions"}],"predecessor-version":[{"id":25500,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages\/21319\/revisions\/25500"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=21319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}